On March 17, 2026, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing the release of a new clinical case study that highlights the benefit of adding CyPath® Lung, a noninvasive test for lung cancer, to the diagnostic pathway for a high-risk patient with multiple pulmonary nodules. The study demonstrated that the CyPath® Lung test provided actionable results, allowing the physician to avoid unnecessary invasive procedures. The patient, a 71-year-old former smoker, had multiple pulmonary nodules, and the CyPath® Lung test indicated a low likelihood of malignancy, leading to a decision to monitor rather than proceed with invasive biopsies. This case study underscores the potential of CyPath® Lung to improve diagnostic clarity and reduce healthcare costs by avoiding unnecessary procedures. The test has shown promising results in clinical studies, demonstrating 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in small nodules. The company believes that this advancement in noninvasive diagnostics will enhance patient care and support physician decision-making. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.